Uematsu T, Nakano M, Kosuge K, Kanamaru M, Nakashima M
Department of Pharmacology, Hamamatsu University School of Medicine, Japan.
Eur J Clin Pharmacol. 1993;44(4):361-4. doi: 10.1007/BF00316473.
We have studied the pharmacokinetics of tulobuterol given transdermally or by aerosol inhalation in healthy male volunteers. Tulobuterol was rapidly absorbed after inhalation, with a tmax of 0.8-1.5 h. The Cmax and the AUC increased linearly with dose. Tulobuterol was well absorbed after transdermal administration, with an absorption lag-time of about 4 h. The Cmax and AUC increased linearly with dose and the tmax was about 9-12 h. The mean percentage of drug absorbed during the application of a patch for 24 h was 82-90% after a single dose and 82-85% during repeated dosing. The mean urinary recoveries as unchanged drug after a single inhalation and patch application were 3-4% and 5-6% respectively. Tulobuterol did not accumulate during repeated inhalation or transdermal application. It was well tolerated, except for an increase in heart rate of 10-20 beats.min-1 after five repeated applications of a 4 mg patch.
我们研究了妥洛特罗在健康男性志愿者中经皮给药和气雾剂吸入后的药代动力学。吸入后妥洛特罗迅速吸收,达峰时间为0.8 - 1.5小时。峰浓度(Cmax)和药时曲线下面积(AUC)随剂量呈线性增加。经皮给药后妥洛特罗吸收良好,吸收滞后时间约为4小时。Cmax和AUC随剂量呈线性增加,达峰时间约为9 - 12小时。单次给药后,24小时贴剂给药期间药物吸收的平均百分比为82 - 90%,重复给药期间为82 - 85%。单次吸入和贴剂给药后,以原形药物形式经尿液回收的平均百分比分别为3 - 4%和5 - 6%。重复吸入或经皮给药期间妥洛特罗不会蓄积。除了4毫克贴剂重复使用5次后心率增加10 - 20次/分钟外,其耐受性良好。